Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27007874 | 0.93 | CHRNA1 (0.53) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL27007774 | 0.86 | NPC1 (0.59) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL5601531 | 0.82 | HDAC6 (0.59) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL8507005 | 0.80 | HDAC6 (0.53) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL30107275 | 0.80 | HDAC6 (0.53) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL1459893 | 0.79 | OGG1 (0.55) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL15007072 | 0.79 | CHRNA1 (0.48) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL8229060 | 0.78 | HDAC1 (0.46) | TP53ALDH1A1GAASMN1; SMN2NPC1 | |
| SCHEMBL29784872 | 0.77 | CHRNA1 (0.51) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL588574 | 0.77 | CHRNA1 (0.51) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822956-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013134415-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-0799226-B1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-5972951-A | Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0799226-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019477-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| US-5510350-A | USEFUL IN TREATMENT OR PROPHYLAXIS OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
| US-5340810-A | Useful in the treatment and prophylaxis of depression and other disorders of the central nervous system | GLAXO GROUP LIMITED (GB) | 1994-08-23 | — | — | US | disclosed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | CHRNA1 4775/4885CHRNG 4695/4885CHRNB1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.